<DOC>
	<DOCNO>NCT00437424</DOCNO>
	<brief_summary>The primary purpose protocol determine effect BMS-582664 patient hepatocellular carcinoma vary level hepatic impairment</brief_summary>
	<brief_title>A Study Brivanib ( BMS-582664 ) Patients With Liver Cancer Mild , Moderate Severe Liver Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Subjects biopsy proven advanced solid tumor Subjects biopsy proven diagnosis hepatocellular carcinoma conform child pugh classification A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hepatocellular cancer</keyword>
	<keyword>Other advance solid malignancy</keyword>
</DOC>